Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Various muscular diseases are associated with changes in the elasticity of the protein titin, but whether these changes are a cause or an effect of disease has been unclear. A study in The Journal of General Physiology helps solve this "chicken or the egg" conundrum and identifies a key player in determining titin's size and stiffness.
Titin is an enormous protein that functions as a molecular spring responsible for the passive elasticity of muscles. It is composed of many individually folded protein domains - including repeating immunoglobulin-like (Ig) domains - that unfold when the protein is stretched and refold when tension is removed.
A team led by researchers from the University of Arizona used a mouse model lacking nine titin Ig domains to investigate the effects of a small increase in titin stiffness. The mutant mice showed a slight curvature of the spine (commonly associated with skeletal muscle disorders), atrophy of the soleus muscle in the leg, atrophy of the diaphragm, and changes in muscle contractility.
In analyzing the mutant mice, the researcher were surprised to observe that in the soleus, which contains one of the largest forms of titin in adult striated muscle, the increase in passive stress was much greater than expected from the loss of only nine Ig domains. And the mutant mice underwent additional changes in titin splicing to produce much smaller, stiffer forms of titin than anticipated. These results indicate that increasing titin's stiffness can be a trigger for - rather than the result of - pathological changes in skeletal muscles.
Further investigation revealed that titin's increased stiffness was caused by an abundance of the splicing factor RBM20 in the mutant mice. Mice created by crossing the mutants with a mouse with decreased RMB20 activity failed to show these additional changes in titin splicing. The results indicate that RMB20 plays a crucial role in determining titin's size and elasticity and could therefore be a possible avenue for modulating the protein in the treatment of various muscular diseases.
Removal of immunoglobulin-like domains from titin’s spring segment alters titin splicing in mouse skeletal muscle and causes myopathy. Buck, D., et al. 2014. J. Gen. Physiol. doi:10.1085/jgp.201311129
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Bones / Orthopedics category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Rockefeller University Press. "Titin's size and stiffness implicated in muscular diseases." Medical News Today. MediLexicon, Intl., 29 Jan. 2014. Web.
18 Apr. 2014. <http://www.medicalnewstoday.com/releases/271791>
Rockefeller University Press. (2014, January 29). "Titin's size and stiffness implicated in muscular diseases." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271791.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.